Quest Diagnostics (DGX) | Financial Analysis & Statements
Quest Diagnostics Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
2.8B
Gross Profit
910.0M
32.43%
Operating Income
386.0M
13.76%
Net Income
256.0M
9.12%
EPS (Diluted)
$2.18
Balance Sheet Metrics
Total Assets
16.2B
Total Liabilities
8.9B
Shareholders Equity
7.3B
Debt to Equity
1.23
Cash Flow Metrics
Operating Cash Flow
439.0M
Free Cash Flow
307.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Quest Diagnostics Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 11.0B | 9.9B | 9.3B | 9.9B | 10.8B |
| Cost of Goods Sold | 7.4B | 6.6B | 6.2B | 6.4B | 6.6B |
| Gross Profit | 3.7B | 3.2B | 3.1B | 3.4B | 4.2B |
| Gross Margin % | 33.2% | 32.9% | 33.0% | 34.7% | 39.0% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 2.0B | 1.8B | 1.6B | 1.9B | 1.7B |
| Other Operating Expenses | -12.0M | 1.0M | 41.0M | 11.0M | -2.0M |
| Total Operating Expenses | 2.0B | 1.8B | 1.7B | 1.9B | 1.7B |
| Operating Income | 1.6B | 1.3B | 1.3B | 1.4B | 2.4B |
| Operating Margin % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| Non-Operating Items | |||||
| Interest Income | 13.0M | 25.0M | 11.0M | 10.0M | 1.0M |
| Interest Expense | 277.0M | 226.0M | 163.0M | 148.0M | 152.0M |
| Other Non-Operating Income | 26.0M | 30.0M | 20.0M | -55.0M | 369.0M |
| Pre-tax Income | 1.3B | 1.2B | 1.1B | 1.2B | 2.6B |
| Income Tax | 314.0M | 273.0M | 248.0M | 264.0M | 597.0M |
| Effective Tax Rate % | 23.8% | 23.2% | 21.9% | 21.4% | 23.0% |
| Net Income | 1.0B | 921.0M | 908.0M | 1.0B | 2.1B |
| Net Margin % | 9.5% | 9.3% | 9.8% | 10.3% | 19.3% |
| Key Metrics | |||||
| EBITDA | 2.2B | 1.9B | 1.7B | 1.8B | 3.2B |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
| Basic Shares Outstanding | 111000000 | 111000000 | 112000000 | 116000000 | 125000000 |
| Diluted Shares Outstanding | 111000000 | 111000000 | 112000000 | 116000000 | 125000000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Quest Diagnostics Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 420.0M | 549.0M | 686.0M | 315.0M | 872.0M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 1.4B | 1.3B | 1.2B | 1.2B | 1.4B |
| Inventory | 189.0M | 188.0M | 190.0M | 192.0M | 208.0M |
| Other Current Assets | 361.0M | 351.0M | 286.0M | 196.0M | 223.0M |
| Total Current Assets | 2.4B | 2.4B | 2.4B | 1.9B | 2.7B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 657.0M | 651.0M | 602.0M | 585.0M | 597.0M |
| Goodwill | 19.5B | 19.5B | 16.6B | 15.5B | 15.4B |
| Intangible Assets | 1.6B | 1.8B | 1.2B | 1.1B | 1.2B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 270.0M | 255.0M | 198.0M | 144.0M | 163.0M |
| Total Non-Current Assets | 13.8B | 13.8B | 11.6B | 10.9B | 10.9B |
| Total Assets | 16.2B | 16.2B | 14.0B | 12.8B | 13.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 307.0M | 287.0M | 378.0M | 324.0M | 357.0M |
| Short-term Debt | 881.0M | 937.0M | 585.0M | 247.0M | 269.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 2.3B | 2.2B | 1.8B | 1.6B | 1.8B |
| Non-Current Liabilities | |||||
| Long-term Debt | 5.7B | 6.2B | 4.9B | 4.5B | 4.5B |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 957.0M | 938.0M | 876.0M | 812.0M | 792.0M |
| Total Non-Current Liabilities | 6.7B | 7.1B | 5.8B | 5.3B | 5.3B |
| Total Liabilities | 8.9B | 9.3B | 7.6B | 6.8B | 7.0B |
| Equity | |||||
| Common Stock | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M |
| Retained Earnings | 10.0B | 9.4B | 8.8B | 8.3B | 7.6B |
| Treasury Stock | 5.2B | 4.9B | 4.8B | 4.7B | 3.5B |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 7.3B | 6.9B | 6.4B | 6.0B | 6.6B |
| Key Metrics | |||||
| Total Debt | 6.6B | 7.1B | 5.5B | 4.7B | 4.8B |
| Working Capital | 100.0M | 223.0M | 557.0M | 347.0M | 988.0M |
Balance Sheet Composition
Quest Diagnostics Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.0B | 921.0M | 908.0M | 1.0B | 2.1B |
| Depreciation & Amortization | 570.0M | 493.0M | 439.0M | 437.0M | 408.0M |
| Stock-Based Compensation | 88.0M | 88.0M | 77.0M | 77.0M | 79.0M |
| Working Capital Changes | 26.0M | -217.0M | -143.0M | 150.0M | 107.0M |
| Operating Cash Flow | 1.9B | 1.3B | 1.3B | 1.7B | 2.6B |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | 3.0M |
| Acquisitions | -101.0M | -2.2B | -611.0M | -144.0M | 424.0M |
| Investment Purchases | - | - | - | - | -3.0M |
| Investment Sales | - | - | - | 5.0M | 0 |
| Investing Cash Flow | -104.0M | -2.1B | -611.0M | -139.0M | 424.0M |
| Financing Activities | |||||
| Share Repurchases | -450.0M | -151.0M | -275.0M | -1.4B | -2.2B |
| Dividends Paid | -353.0M | -331.0M | -314.0M | -305.0M | -309.0M |
| Debt Issuance | 410.0M | 1.8B | 2.6B | 0 | 0 |
| Debt Repayment | -1.0B | -303.0M | -1.8B | -2.0M | -2.0M |
| Financing Cash Flow | -1.5B | 1.0B | 88.0M | -1.9B | -2.7B |
| Free Cash Flow | 1.4B | 909.0M | 864.0M | 1.3B | 1.8B |
| Net Change in Cash | 288.0M | 201.0M | 750.0M | -248.0M | 318.0M |
Cash Flow Trend
Quest Diagnostics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
22.68
Forward P/E
17.81
Price to Book
3.15
Price to Sales
2.02
PEG Ratio
1.49
Profitability Ratios
Profit Margin
9.08%
Operating Margin
13.71%
Return on Equity
14.54%
Return on Assets
6.39%
Financial Health
Current Ratio
1.18
Debt to Equity
82.71
Per Share Data
EPS (TTM)
$9.04
Book Value per Share
$65.18
Revenue per Share
$101.83
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| DGX | 22.1B | 22.68 | 3.15 | 14.54% | 9.08% | 82.71 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Idexx Laboratories | 44.7B | 42.92 | 27.85 | 66.20% | 24.62% | 60.83 |
| Agilent Technologies | 32.7B | 25.67 | 4.76 | 19.95% | 18.26% | 51.39 |
| Waters | 30.5B | 28.90 | 7.24 | 29.28% | 20.30% | 60.28 |
Financial data is updated regularly. All figures are in the company's reporting currency.






